BALCHEM (BCPC) SEC Filings

Balchem Corporation (BCPC) reported third-quarter 2026 net sales of $290.7 million, up 8.6% from the prior-year quarter, and GAAP net earnings of $46.7 million, up 16.0%. Adjusted EBITDA was $80.3 million, up 12.4%; diluted GAAP earnings per share were $1.46 versus $1.24. Sales and earnings from operations increased in all three reporting segments. Human Nutrition and Health sales were $188.2 million, Animal Nutrition and Health sales were $63.0 million, and Specialty Products sales were $37.3 million.

Operating cash flow was $69.8 million and free cash flow was $57.9 million. At September 30, 2026, cash was $66.3 million and revolving-loan debt was $124.0 million; Balchem reported net debt of $57.7 million and net-debt leverage of 0.2 times. The company repurchased $27.4 million of common stock during the quarter and approximately $127 million over the trailing twelve months. It also paid $27.8 million in income taxes and $12.5 million for capital expenditures and acquired intangible assets during the quarter.

BALCHEM CORP SVP and Chief R&D Officer Ren Anthony Gonzalez reported 6,335 directly held common shares and 884 common shares held indirectly through a 401(k) Plan as of September 16, 2026. A footnote to the common-stock entry states that ownership of 6,133 restricted shares vests between 1 and 3 years following the various grant dates and is subject to transfer restrictions. Gonzalez also reported an employee option covering 240 common shares, with a $143.43 exercise price, an exercise date of February 8, 2027, and an expiration date of February 8, 2034.

Balchem Corporation reported solid Q2 2026 results, with net sales of $283,997 thousand, up 11.2% year over year, and net earnings of $44,615 thousand, up 16.6%. Diluted EPS was $1.39 for the quarter and $2.63 for the first six months.

Growth was broad-based: Human Nutrition & Health sales increased 10.0%, Animal Nutrition & Health 15.0%, and Specialty Products 8.9%. Gross margin was 36.5% in the quarter versus 36.4% a year earlier, and 36.9% year to date versus 35.8%, helped by higher volumes, pricing, and mix, partly offset by higher input costs.

Operating cash flow reached $86,772 thousand for the first half, funding $17,138 thousand of capital investments, $30,772 thousand of dividends, and $44,484 thousand of share repurchases. Net borrowings under the revolving loan were $152,000 thousand with $398,000 thousand of availability, and a July 2026 amendment increased total revolving capacity to $650,000 thousand and extended maturity to 2031.

Balchem Corporation reported a strong second quarter of 2026, with net sales of $284.0 million, up 11.2% from a year earlier, and GAAP net earnings of $44.6 million, up 16.6%. Adjusted EBITDA was $77.9 million, an increase of 12.6%, while diluted GAAP EPS rose to $1.39 and adjusted EPS to $1.49. Free cash flow was $36.2 million on cash from operations of $46.7 million.

All three segments grew, with Human Nutrition and Health delivering record quarterly sales of $176.9 million and record earnings from operations of $42.4 million; Animal Nutrition and Health sales rose 15.0% to $64.5 million, and Specialty Products posted record sales of $40.5 million. Gross margin rose to $103.7 million, or 36.5% of sales. Balchem extended its senior secured revolving credit facility to July 24, 2031 and increased capacity from $550 million to $650 million. Net debt was $88.8 million with a net leverage ratio of 0.3x, and the company repurchased approximately $29 million of stock in the quarter and $114 million over the trailing twelve months.

Balchem Corporation amended its Amended and Restated Credit Agreement on July 24, 2026, increasing the aggregate revolving commitment from $550 million to $650 million and extending the facility’s maturity from July 27, 2027 to July 24, 2031.

The amendment permits foreign subsidiary Balchem B.V. to borrow, eliminates a 10 basis point adjustment to the applicable SOFR rate, and reduces applicable margins for loans at Tier 3 and 4 Consolidated Net Leverage Ratios by 12.5 basis points in each tier, with corresponding base rate reductions. An Omnibus Reaffirmation and Amendment Agreement confirms that existing security and pledge arrangements and related liens and guarantees remain in effect.

Balchem Corporation reported the results of its Annual Meeting of Shareholders held on June 18, 2026. Shareholders elected Class 3 directors David Fischer and Daniel Knutson to serve until the 2029 annual meeting, with each receiving over 26 million votes in favor.

Shareholders also ratified the appointment of RSM US LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. In addition, they gave advisory approval to the compensation of the company’s named executive officers through a say‑on‑pay vote.

Balchem Corporation delivered higher first-quarter 2026 results, with net sales rising to $270.7 million from $250.5 million and net earnings increasing to $40.3 million from $37.1 million. Diluted EPS grew to $1.25 from $1.13.

Gross margin expanded to 37.3% of sales from 35.2%, supported by growth across Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products, partly offset by higher raw material and compensation costs. Operating margin remained strong at about 20.5%.

Operating cash flow was $40.1 million, funding $6.3 million of capital and intangible investments, $30.8 million of dividends, and $15.7 million of share repurchases. Total assets were $1.69 billion, with a $169 million revolving loan balance and stockholders’ equity of $1.29 billion.

Comprehensive income was reduced by a $9.8 million other comprehensive loss, mainly from foreign currency translation. Management notes ongoing monitoring of geopolitical tensions and evolving U.S. tariff policies but does not currently expect a material impact on future results or cash flows based on available information.

Balchem Corporation reported strong results for the first quarter of 2026, showing growth across all segments. Net sales were $270.7 million, up 8.1% from a year earlier, with GAAP net earnings of $40.3 million, up 8.7%. Adjusted EBITDA reached $74.3 million, an increase of 12.1%.

GAAP diluted earnings per share were $1.25 versus $1.13 in the prior-year quarter, while adjusted diluted EPS was $1.33 versus $1.22. Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products all delivered higher sales and earnings from operations, with Specialty Products achieving record earnings.

Cash flows from operations were $40.1 million and free cash flow was $33.8 million. Balchem returned capital through a $30.8 million dividend and $15.7 million of share repurchases and ended the quarter with $72.9 million in cash, $169.0 million of revolving debt and net debt of $96.1 million.

Vanguard Capital Management reported beneficial ownership of 1,680,971 shares of Balchem Corp common stock, representing 5.24% of the class as of 03/31/2026. The filing shows sole voting power over 248,883 shares and sole dispositive power over 1,680,971 shares. The Schedule 13G filing is signed on 04/29/2026 by Ashley Grim as Head of Global Fund Administration and states the holdings include securities held for Vanguard funds and managed accounts.